A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma

Table 1

Prospective studies included in meta-analyses.

Study, Year	Regimen	PTCL subgroup*	n	CR%	OS
Coiffer et al., 1990 [3]	ACVB (LNH84)	PTCL-combined	108	72.0
Liang et al., 1992 [11]	BACOP ± Methotrexate	PTCL-combined	42	67.0	3 yr 52%
Siegert et al., 1992 [12]	Pred ± COPBLAM/IMVP	AITL	39	33.0	3 yr 41%
Karakas et al., 1996 [13]	VACPE	PTCL-combined	27	77.0	5 yr 48%
Gisselbrecht et al., 1998 [4]	Anthracycline-based	PTCL-combined	288	54.0	5 yr 41%
		ALCL	60	72.0	5 yr 64%
		Non-ALCL PTCL	228	49.0	5 yr 35%
Daum et al., 2003 [14]	CHOP	ETTL	23	35.0	2 yr 49%
Reimer et al., 2004 [15]	CHOP	PTCL-combined	30	43.3
		PTCL-NOS	12	41.7
		AITL	12	33.3
		ALK Neg ALCL	4	50.0
		NK/T nasal	2	100.0
Wöhrer et al., 2004 [16]	CHOEP	ETTL	10	30.0
Kim et al., 2006 [17]	CHOP-EG	PTCL-combined	26	61.5	1 yr 70%
		PTCL-NOS	14	57.1
		AITL	2	50.0
		ALK Neg ALCL	2	100.0
		NK/T nasal	8	62.5
Lee et al., 2006 [18]	DI-CHOP + RT	NK/T nasal	17	76.5	3 yr 67%
Sung et al., 2006 [19]	CEOP-B	PTCL-combined	52	17.3
		PTCL-NOS	41	17.1
		AITL	5	40.0
		ALCL	4	0.0
Bishton and Haynes, 2007 [20]	HDCT + PBSCT	ETTL	6	83.3
Takamatsu et al., 2010 [21]	THP-COP	Non-ALCL PTCL	17	41.0	3 yr 35%

PTCL: peripheral T-cell lymphoma; n: number of patients; CR: complete response; OS: overall survival; ACVB: doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; BACOP: Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone; Pred, prednisolone; COPBLAM: cyclophosphamide, vincristine, and prednisone with bleomycin, doxorubicin, and procarbazine; IMVP: ifosfamide, methotrexate, and etoposide; VACPE: vincristine, doxorubicin, cyclophosphamide, prednisone, and etoposide; NK/T nasal, NK/T-cell lymphoma nasal type; NOS: not otherwise specified; ALCL: anaplastic large cell lymphoma; AITL: angioimmunoblastic T-cell lymphoma; ETTL: enteropathy-type T-cell lymphoma; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; RT: radiation therapy; CMT: combined modality treatment; V: vincristine; syst, systemic; Neg: negative; CHOEP: cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone; CT: chemotherapy; CVAD: cyclophosphamide, doxorubicin, vincristine, and dexamethasone; VIP: vinblastine, ifosfamide, and cisplatin; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; EG: etoposide and gemcitabine; DI: dose-intensive; CEOP-B: cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin; HDCT: high-dose chemotherapy; PBSCT: peripheral blood stem cell transplant; THP-COP: pirarubicin, cyclophosphamide, vincristine, and prednisone.
*PTCL-combined represents the whole group of PTCL patients. In cases where studies separated ALK-positive and ALK-negative ALCL and provided separate results for the two subgroups, ALK-positive patients were excluded from the meta-analysis. Non-ALCL PTCL indicates PTCL without any ALCL subtype included.